Skip to Main Content

For only the second time since launching nearly two years ago, the AMR Action Fund has announced an investment in a fledgling biotech company as it tries to underwrite efforts to develop badly needed medicines for combating antibiotic resistance.

In its latest move, the fund is providing $7.5 million to BioVersys, which is developing an antibiotic to combat a type of bacteria that affects people with compromised immune systems and is increasingly responsible for infections in hospitalized patients. The drug, which is about to enter Phase 2 testing, is targeting hospital-acquired pneumonia, pneumonia associated with ventilators, and blood stream infections that originate from pneumonia.


“There is a very large need for such antibiotics,” said BioVersys chief executive officer Marc Gitzinger, who noted the investment is part of a larger, $32.6 million round of funding known as Series C. “In general, antibiotic resistance is a growing problem, but it’s also been incredibly difficult to get classic venture capital for companies working in this field. The AMR investment is reassuring.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.